Committed to transforming the lives of patients with severe genetic and rare diseases


With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio (NASDAQ: BLUE) has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio's gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ BB305 product candidate, currently in three clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. bluebird bio's oncology pipeline is built upon the company's leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio's lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company's pipeline.


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.bluebirdbio.com

Recent News

February 3, 2017
bluebird bio Announces First Patient Treated with LentiGlobin™ Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease

January 4, 2017
bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference

December 15, 2016
bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner

Neil Exter
Partner

Philip Reilly, M.D., J.D.
Venture Partner